Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ares Commercial Real Estate Corp (ACRE): Are Hedge Funds Right About This Stock?

Page 1 of 2

Many investors, including Carl Icahn or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the third quarter, many investors lost money due to unpredictable events such as the concerns over Valeant’s drug pricing policy that led to an overall drop among pharma stocks. Nevertheless, many of the stocks that tanked in the third quarter still sport strong fundamentals and their decline was more related to the general market sentiment rather than their individual performance and hedge funds kept their bullish stance. In this article we will find out how hedge fund sentiment to Ares Commercial Real Estate Corp (NYSE:ACRE) changed recently.

Despite an 8.28% dividend yield and a 5% year-to-date gains, Ares Commercial Real Estate Corp (NYSE:ACRE) investors should be aware of a decrease in support from the world’s most elite money managers lately. ACRE was in 13 hedge funds’ portfolios at the end of the third quarter of 2015. There were 14 hedge funds in our database with ACRE positions at the end of the previous quarter. At the end of this article we will also compare ACRE to other stocks including Xcerra Corp (NASDAQ:XCRA), Arrowhead Research Corp (NASDAQ:ARWR), and Ocean Rig UDW Inc (NASDAQ:ORIG) to get a better sense of its popularity.

Follow Ares Commercial Real Estate Corp (NYSE:ACRE)
Trade (NYSE:ACRE) Now!

According to most traders, hedge funds are seen as unimportant, old financial tools of yesteryear. While there are over an 8000 funds with their doors open today, Our experts hone in on the leaders of this club, about 700 funds. These investment experts oversee the majority of the hedge fund industry’s total capital, and by observing their highest performing equity investments, Insider Monkey has unsheathed various investment strategies that have historically outstripped the S&P 500 index. Insider Monkey’s small-cap hedge fund strategy defeated the S&P 500 index by 12 percentage points per annum for a decade in their back tests.

Keeping this in mind, let’s view the key action surrounding Ares Commercial Real Estate Corp (NYSE:ACRE).

How are hedge funds trading Ares Commercial Real Estate Corp (NYSE:ACRE)?

At the end of the third quarter, a total of 13 of the hedge funds tracked by Insider Monkey were long this stock, down by 7% from one quarter earlier. With the smart money’s positions undergoing their usual ebb and flow, there exists a select group of noteworthy hedge fund managers who were increasing their holdings considerably (or already accumulated large positions).

When looking at the institutional investors followed by Insider Monkey, J. Alan Reid, Jr.’s Forward Management has the most valuable position in Ares Commercial Real Estate Corp (NYSE:ACRE), worth close to $6.9 million, comprising 0.6% of its total 13F portfolio. The second most bullish fund is Renaissance Technologies, with a $4.5 million position; the fund has less than 0.1%% of its 13F portfolio invested in the stock. Other hedge funds and institutional investors that are bullish include Israel Englander’s Millennium Management, Ken Griffin’s Citadel Investment Group, and Amy Minella’ Cardinal Capital.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!